Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
AstraZeneca
Abramson Cancer Center at Penn Medicine
Massachusetts General Hospital
OHSU Knight Cancer Institute
Canadian Cancer Trials Group
Ludwig Institute for Cancer Research
Icahn School of Medicine at Mount Sinai
AstraZeneca